Next, we tested whether knockdown of Metap1 or Metap2 might provide synergistic effects to PI3K inhibition not only in murine breast cancer cells, but also in human MCF7-TA and MDAMB-TA cells representing luminal A-type and triple-negative breast cancers, respectively. Here, METAP2 is linked to breast cancer.